Panovir 100 MG (Sofosbuvir+Velpatasvir)
Product Name : Panovir
Generic Name : Sofosbuvir+Velpatasvir
Formulation : Tablet
Available Pack Size : 28’s
Available Strengths : 100 mg
Registrations : Export Only
Product Information
Panovir (Sofosbuvir + Velpatasvir) 400mg/100mg is a pangenotypic, fixed-dose combination direct-acting antiviral (DAA) used to treat chronic Hepatitis C virus (HCV) infection, genotypes 1 through 6, in adults and eligible paediatric patients, with or without compensated cirrhosis. It works by combining two complementary mechanisms of action to block HCV replication: Sofosbuvir inhibits the viral NS5B polymerase, and Velpatasvir inhibits the viral NS5A protein. Global supplier: Mediaid Pharmacy with worldwide shipping.
Note: “Panovir 100mg” refers to the Velpatasvir component of the tablet. Each Panovir tablet is a fixed-dose combination containing Sofosbuvir 400mg and Velpatasvir 100mg, matching the internationally standard adult dosing strength for this combination. Please confirm this matches your product’s actual formulation before publishing.
Basic Product Information of Panovir (Sofosbuvir + Velpatasvir)
| Brand Name | Panovir (Sofosbuvir + Velpatasvir) |
| Generic Name | Sofosbuvir INN + Velpatasvir INN |
| Drug Class | Direct-Acting Antiviral (DAA): NS5B Polymerase Inhibitor + NS5A Inhibitor |
| Available Strengths | Sofosbuvir 400mg + Velpatasvir 100mg per tablet |
| Formulation | Film-Coated Tablet |
| Pack Size | 28 Tablets per Pack (4-week supply). A full standard treatment course of 12 weeks requires 3 packs. |
| Primary Indication | Chronic Hepatitis C Virus (HCV) Infection, Genotypes 1-6 |
| Regulatory Approvals | USFDA Approved (HCV genotypes 1-6, adults and paediatric patients 3 years and older). EMA Approved (HCV genotypes 1-6). |
| Originator Brand | Epclusa by Gilead Sciences |
| Manufacturer | [Manufacturer name to be confirmed], Bangladesh |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Registration | Export Only |
| Storage Conditions | Store below 30 degrees Celsius. Keep in a dry place away from light and moisture. Keep out of the reach of children. |
How Panovir (Sofosbuvir + Velpatasvir) Works
Panovir combines two direct-acting antivirals (DAAs) that target different steps of the Hepatitis C virus (HCV) life cycle. Sofosbuvir is a nucleotide analogue that inhibits the HCV NS5B RNA-dependent RNA polymerase, an enzyme the virus needs to replicate its genetic material. Velpatasvir is a pangenotypic inhibitor of the HCV NS5A protein, which is required for viral RNA replication and assembly of new virus particles.
By blocking these two distinct, essential viral proteins simultaneously, Panovir suppresses HCV replication across genotypes 1 through 6, allowing the body’s immune system to clear the infection over the course of treatment. Successful treatment is measured as a sustained virologic response (SVR12), meaning HCV RNA remains undetectable 12 weeks after completing therapy, which is considered a virologic cure.
Panovir is a once-daily oral tablet, offering a simple, interferon-free treatment course that has largely replaced older, less tolerable Hepatitis C therapies.
Indications for Panovir (Sofosbuvir + Velpatasvir)
Panovir (Sofosbuvir + Velpatasvir) is indicated for the following:
|
Chronic HCV, No Cirrhosis or Compensated Cirrhosis For adults and paediatric patients 3 years and older with chronic HCV genotype 1-6 infection, without cirrhosis or with compensated (Child-Pugh A) cirrhosis, as a single-agent 12-week course. |
Chronic HCV with Decompensated Cirrhosis For adult patients with chronic HCV genotype 1-6 infection and decompensated (Child-Pugh B or C) cirrhosis, used in combination with ribavirin for 12 weeks. |
Benefits of Panovir (Sofosbuvir + Velpatasvir)
|
Pangenotypic Coverage Panovir treats all six major HCV genotypes with a single regimen, removing the need for genotype-specific therapy selection in most patients. |
Simple Once-Daily Tablet A single tablet taken once daily, with or without food, for a fixed 12-week course, replacing older multi-pill, interferon-based regimens. |
High Cure Rates Clinical studies of the Sofosbuvir/Velpatasvir combination have demonstrated high sustained virologic response (SVR12) rates across genotypes and cirrhosis status. |
|
Affordable Alternative to Epclusa Panovir contains the same active ingredients as Epclusa by Gilead Sciences, at a significantly lower cost, widening access to a curative Hepatitis C therapy. |
No Renal Dose Adjustment No dosage adjustment is required for any degree of renal impairment, including patients on dialysis, simplifying prescribing in patients with kidney disease. |
WHO-GMP and cGMP Certified Manufactured under strict WHO-GMP, cGMP, and ISO-certified standards, ensuring every batch of Panovir meets consistent quality, safety, and efficacy requirements. |
How to Take Panovir (Sofosbuvir + Velpatasvir)
Route: Oral, taken by mouth
Standard dose, no cirrhosis or compensated cirrhosis: One tablet (Sofosbuvir 400mg/Velpatasvir 100mg) once daily for 12 weeks, as a single agent.
Standard dose, decompensated cirrhosis: One tablet once daily for 12 weeks, given together with ribavirin as directed by the prescribing physician.
With food: Can be taken with or without food, at any time of the day.
Renal impairment: No dose adjustment is required for any degree of renal impairment, including patients on dialysis.
Hepatic impairment: No dose adjustment is required for mild, moderate, or severe hepatic impairment; patients with decompensated cirrhosis require added ribavirin as above.
Missed dose: If a dose is missed and remembered within 18 hours of the usual time, take it as soon as possible and continue the normal schedule. If more than 18 hours have passed, skip the missed dose and take the next dose at the regular time. Do not double the dose.
Paediatric use: Established in patients 3 years of age and older; not established in children under 3 years.
Monitoring and Dosage Adjustments
Regular monitoring is essential during Panovir treatment. Your healthcare provider will test for Hepatitis B virus (HBsAg and anti-HBc) before starting therapy, and monitor HCV RNA levels to confirm treatment response and, ultimately, cure (SVR12). Patients taking amiodarone require close cardiac monitoring due to a risk of serious bradycardia, and generally should not be co-prescribed Panovir. Liver function should be monitored throughout treatment, particularly in patients with cirrhosis. Report any unusual fatigue, dizziness, fainting, or slow heartbeat to your doctor immediately.
Drug Interactions and Important Information
Co-administration of Panovir is not recommended with proton-pump inhibitors, phenobarbital, phenytoin, rifampin, rifabutin, rifapentine, efavirenz, tipranavir/ritonavir, and St. John’s Wort, as these can significantly decrease Sofosbuvir and/or Velpatasvir concentrations and reduce efficacy. Concomitant use with amiodarone is not recommended due to a risk of serious symptomatic bradycardia, particularly when Panovir is used with other direct-acting antivirals.
H2-receptor antagonists may be taken simultaneously with or staggered from Panovir at comparable or lower doses; antacids should be separated from Panovir dosing by at least 4 hours. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Panovir.
Side Effects and Precautions
|
Common Side Effects Headache Fatigue Nausea Asthenia (weakness) Insomnia |
Serious Warnings and Precautions Hepatitis B virus reactivation in HCV/HBV co-infected patients (Boxed Warning). Serious symptomatic bradycardia when co-administered with amiodarone. Reduced efficacy with certain interacting medications (see Drug Interactions). If used with ribavirin for decompensated cirrhosis, refer to ribavirin’s own warnings and precautions, including its contraindication in pregnancy. |
Who Should Use Panovir (Sofosbuvir + Velpatasvir)?
Panovir is suitable for adults and paediatric patients 3 years and older diagnosed with chronic Hepatitis C virus infection, genotypes 1 through 6, whether treatment-naive or previously treated, with or without compensated cirrhosis. Patients with decompensated cirrhosis require the addition of ribavirin under specialist supervision. It is prescribed by hepatologists, gastroenterologists, infectious disease specialists, and other physicians experienced in managing HCV infection. HBV testing and baseline liver assessment are required before starting treatment.
Manufacturer
Panovir (Sofosbuvir + Velpatasvir) is manufactured in Bangladesh under strict WHO-GMP, cGMP, and ISO-certified standards for export markets, offering an affordable and bioequivalent alternative to Epclusa by Gilead Sciences at a fraction of the cost. [Please confirm the exact manufacturer name so it can be added here and in the specs table above.]
Global Supplier: Mediaid Pharmacy with Worldwide Shipping
Mediaid Pharmacy is a trusted global supplier of specialty antiviral medications. We ensure Panovir (Sofosbuvir + Velpatasvir) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.
Why Choose Panovir (Sofosbuvir + Velpatasvir) from Mediaid Pharmacy?
Panovir represents a highly effective, pangenotypic treatment option for patients with chronic Hepatitis C. As the generic equivalent of Epclusa by Gilead Sciences, it delivers the same active ingredients, Sofosbuvir and Velpatasvir, with the same proven dual-mechanism antiviral action at a dramatically more affordable price. Manufactured under WHO-GMP and cGMP standards and distributed globally by Mediaid Pharmacy, Panovir gives patients worldwide access to a potentially curative Hepatitis C therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Sofosbuvir/Velpatasvir option with worldwide delivery, Panovir from Mediaid Pharmacy is the trusted choice.
Frequently Asked Questions About Panovir (Sofosbuvir + Velpatasvir)
What is Panovir (Sofosbuvir + Velpatasvir) used for?
Panovir is a fixed-dose combination antiviral used to treat chronic Hepatitis C virus (HCV) infection, covering genotypes 1 through 6, in adults and children 3 years and older. It works by blocking two proteins the virus needs to replicate, and can lead to a virologic cure (SVR12) after a 12-week course. It is used for Hepatitis C, not Hepatitis B or HIV.
How should I take Panovir (Sofosbuvir + Velpatasvir)?
Panovir is taken as one tablet by mouth once daily, with or without food, for a standard course of 12 weeks. Patients with decompensated cirrhosis take it together with ribavirin. Always follow your prescribing physician’s exact instructions and complete the full course even if you feel well, to reduce the risk of treatment failure.
What strength and pack size is Panovir available in?
Panovir tablets contain Sofosbuvir 400mg and Velpatasvir 100mg, supplied in packs of 28 tablets, which covers 4 weeks of the standard once-daily regimen. A complete 12-week treatment course requires 3 packs.
Is Panovir the same as Epclusa (Sofosbuvir/Velpatasvir by Gilead)?
Yes. Panovir is the generic equivalent of Epclusa. Both contain the same active ingredients, Sofosbuvir and Velpatasvir, in the same fixed-dose combination and strength. Panovir delivers the same clinical benefits as Epclusa at a significantly lower cost, making it a more accessible option for patients worldwide.
What are the side effects of Panovir (Sofosbuvir + Velpatasvir)?
Panovir is generally well tolerated. Common side effects include headache, fatigue, nausea, weakness, and insomnia. The most important safety concern is the risk of Hepatitis B virus reactivation in patients co-infected with HBV, which is why HBV testing is required before starting treatment. Always consult your physician for a complete assessment of your individual risks and benefits.
Can Panovir be used with other medications?
Certain medications, including proton-pump inhibitors, some anticonvulsants, some antibiotics (rifamycins), efavirenz, and amiodarone, are not recommended with Panovir as they can reduce its effectiveness or, in the case of amiodarone, cause dangerously slow heart rate. Always review your complete medication list, including supplements and herbal products, with your prescribing physician before starting Panovir.
Is Panovir safe during pregnancy or breastfeeding?
Panovir alone has limited pregnancy safety data, and if used with ribavirin for decompensated cirrhosis, ribavirin itself is contraindicated in pregnancy and requires strict contraception precautions for patients and their partners. Please consult your physician before starting treatment if you are pregnant, planning to become pregnant, or breastfeeding.
Can I order Panovir (Sofosbuvir + Velpatasvir) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Panovir (Sofosbuvir + Velpatasvir) globally with worldwide shipping. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email us at info@mediaidpharmacy.com to enquire about pricing, availability, and delivery to your country.
Order Panovir (Sofosbuvir + Velpatasvir) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
